CAR-T cell therapy: Efficacy in management of cancers, adverse effects, dose-limiting toxicities and long-term follow up
<p dir="ltr">Chimeric Antigen Receptor T-cell (CAR-T) therapy has emerged as a groundbreaking and highly promising approach for the management of cancer. This paper reviews the efficacy of CAR-T therapy in the treatment of various <u>hematological malignancies</u>, also,...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , , , , , , |
| Published: |
2024
|
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1864513542168772608 |
|---|---|
| author | Mohamed Elmarasi (14614276) |
| author2 | Islam Elkonaissi (14821557) Ahmed Adel Elsabagh (21660956) Engy Elsayed (17835426) Abdelrahman Elsayed (6288913) Basant Elsayed (17714559) Ibrahim Elmakaty (14614270) Mohamed Yassin (4166515) |
| author2_role | author author author author author author author |
| author_facet | Mohamed Elmarasi (14614276) Islam Elkonaissi (14821557) Ahmed Adel Elsabagh (21660956) Engy Elsayed (17835426) Abdelrahman Elsayed (6288913) Basant Elsayed (17714559) Ibrahim Elmakaty (14614270) Mohamed Yassin (4166515) |
| author_role | author |
| dc.creator.none.fl_str_mv | Mohamed Elmarasi (14614276) Islam Elkonaissi (14821557) Ahmed Adel Elsabagh (21660956) Engy Elsayed (17835426) Abdelrahman Elsayed (6288913) Basant Elsayed (17714559) Ibrahim Elmakaty (14614270) Mohamed Yassin (4166515) |
| dc.date.none.fl_str_mv | 2024-05-23T12:00:00Z |
| dc.identifier.none.fl_str_mv | 10.1016/j.intimp.2024.112312 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/CAR-T_cell_therapy_Efficacy_in_management_of_cancers_adverse_effects_dose-limiting_toxicities_and_long-term_follow_up/29715746 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Immunology Oncology and carcinogenesis CAR-T cell therapy Progression-free survival (PFS) Dose-limiting toxicities ICANS Cytokine release syndrome (CRS) |
| dc.title.none.fl_str_mv | CAR-T cell therapy: Efficacy in management of cancers, adverse effects, dose-limiting toxicities and long-term follow up |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <p dir="ltr">Chimeric Antigen Receptor T-cell (CAR-T) therapy has emerged as a groundbreaking and highly promising approach for the management of cancer. This paper reviews the efficacy of CAR-T therapy in the treatment of various <u>hematological malignancies</u>, also, with a mention of its effect on solid tumors, for which they have not received FDA approval yet. Different common and uncommon side effects are also discussed in this paper, with attention to the effect of each drug separately. By reviewing the recommendations of the FDA for CAR-T therapy research, we have extensively discussed dose-limiting toxicities. This further highlights the need for precise dosing strategies, striking a balance between therapeutic benefits and potential risks. Additionally, we reviewed the long-term follow-up of patients receiving CAR-T therapy to gain valuable insights into response durability and late-onset effects.</p><h2>Other Information</h2><p dir="ltr">Published in: International Immunopharmacology<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.intimp.2024.112312" target="_blank">https://dx.doi.org/10.1016/j.intimp.2024.112312</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_8ab38c86724029b044a0749d426601d2 |
| identifier_str_mv | 10.1016/j.intimp.2024.112312 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/29715746 |
| publishDate | 2024 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | CAR-T cell therapy: Efficacy in management of cancers, adverse effects, dose-limiting toxicities and long-term follow upMohamed Elmarasi (14614276)Islam Elkonaissi (14821557)Ahmed Adel Elsabagh (21660956)Engy Elsayed (17835426)Abdelrahman Elsayed (6288913)Basant Elsayed (17714559)Ibrahim Elmakaty (14614270)Mohamed Yassin (4166515)Biomedical and clinical sciencesImmunologyOncology and carcinogenesisCAR-T cell therapyProgression-free survival (PFS)Dose-limiting toxicitiesICANSCytokine release syndrome (CRS)<p dir="ltr">Chimeric Antigen Receptor T-cell (CAR-T) therapy has emerged as a groundbreaking and highly promising approach for the management of cancer. This paper reviews the efficacy of CAR-T therapy in the treatment of various <u>hematological malignancies</u>, also, with a mention of its effect on solid tumors, for which they have not received FDA approval yet. Different common and uncommon side effects are also discussed in this paper, with attention to the effect of each drug separately. By reviewing the recommendations of the FDA for CAR-T therapy research, we have extensively discussed dose-limiting toxicities. This further highlights the need for precise dosing strategies, striking a balance between therapeutic benefits and potential risks. Additionally, we reviewed the long-term follow-up of patients receiving CAR-T therapy to gain valuable insights into response durability and late-onset effects.</p><h2>Other Information</h2><p dir="ltr">Published in: International Immunopharmacology<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.intimp.2024.112312" target="_blank">https://dx.doi.org/10.1016/j.intimp.2024.112312</a></p>2024-05-23T12:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1016/j.intimp.2024.112312https://figshare.com/articles/journal_contribution/CAR-T_cell_therapy_Efficacy_in_management_of_cancers_adverse_effects_dose-limiting_toxicities_and_long-term_follow_up/29715746CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/297157462024-05-23T12:00:00Z |
| spellingShingle | CAR-T cell therapy: Efficacy in management of cancers, adverse effects, dose-limiting toxicities and long-term follow up Mohamed Elmarasi (14614276) Biomedical and clinical sciences Immunology Oncology and carcinogenesis CAR-T cell therapy Progression-free survival (PFS) Dose-limiting toxicities ICANS Cytokine release syndrome (CRS) |
| status_str | publishedVersion |
| title | CAR-T cell therapy: Efficacy in management of cancers, adverse effects, dose-limiting toxicities and long-term follow up |
| title_full | CAR-T cell therapy: Efficacy in management of cancers, adverse effects, dose-limiting toxicities and long-term follow up |
| title_fullStr | CAR-T cell therapy: Efficacy in management of cancers, adverse effects, dose-limiting toxicities and long-term follow up |
| title_full_unstemmed | CAR-T cell therapy: Efficacy in management of cancers, adverse effects, dose-limiting toxicities and long-term follow up |
| title_short | CAR-T cell therapy: Efficacy in management of cancers, adverse effects, dose-limiting toxicities and long-term follow up |
| title_sort | CAR-T cell therapy: Efficacy in management of cancers, adverse effects, dose-limiting toxicities and long-term follow up |
| topic | Biomedical and clinical sciences Immunology Oncology and carcinogenesis CAR-T cell therapy Progression-free survival (PFS) Dose-limiting toxicities ICANS Cytokine release syndrome (CRS) |